RNA-based Reprogramming of Human Primary Fibroblasts into Induced Pluripotent Stem Cells

McGrath, Patrick S.; Diette, N.; Kogut, Igor; Bilousova, Ganna

doi:10.3791/58687

Cited by 12 publications

(6 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Basic research in an orthotopic xenograft mouse model of glioblastoma showed that cell‐based therapy with miR‐302/367‐expressing cells inhibits tumor growth . Currently, researchers can generate high‐quality iPSCs from most fibroblast sources by transfection with reprogramming‐modified mRNAs and mature ESC‐specific miR‐367/302 mimics . Cancer stem cells also represent a new approach to understanding the origin of cancer.…”

Section: Microrna‐302 Cluster Is An Emerging Potential Biomarker or Tmentioning

confidence: 99%

Application of the microRNA‐302/367 cluster in cancer therapy

Liu

Wang

et al. 2020

Cancer Science

View full text Add to dashboard Cite

This is an open access article under the terms of the Creat ive Commo ns Attri butio n-NonCo mmerc ial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. , glycogen synthase kinase-3β; HCC, hepatocellular carcinoma; HECC, human endometrial carcinoma cell; hESC, human embryonic stem cell; IGF-1R, insulin-like growth factor 1 receptor; iPSCs, induced pluripotent stem cells; JNK, c-Jun NH2-terminal kinase; KLF4, Kruppel Like Factor 4; KPNA2, NF-κB-inducing kinase and karyopherin α2; LATS2, large tumor suppressor kinase 2; lncRNA, long noncoding RNA; LSCC, laryngeal squamous cell carcinoma; Mcl-1, myeloid cell leukemia sequence 1; MIAT, myocardial infarction-associated transcript; miRNA, microRNA; mirPS, miRNA-induced pluripotent stem; MTDH, metadherin; ncRNA, noncoding RNA; NK, natural killer; Notch4, notch receptor 4; NR2F2, nuclear receptor subfamily 2 group F member 2; OC, ovarian cancer; OCT, organic cation/carnitine transporter; PCa, prostate cancer; P-gp, P-glycoprotein; PRP-1, proline-rich polypeptide 1; RACK1, receptor for activated C-kinase 1; S1pr1, sphingosine-1-phosphate receptor 1; SDC1, syndecan 1; SDF1, stromal cell-derived factor 1; SHH, sonic hedgehog; SOX2, SRY-box transcription factor 2; Tcf3, transcription factor 3; SSEA-4, stage-specific embryonic antigen-4; YAP, Yes-associated transcriptional regulator. AbstractAs a novel class of noncoding RNAs, microRNAs (miRNAs) can effectively silence their target genes at the posttranscriptional level. Various biological processes, such as cell proliferation, differentiation, and motility, are regulated by miRNAs. In different diseases and different stages of disease, miRNAs have various expression patterns, which makes them candidate prognostic markers and therapeutic targets.Abnormal miRNA expression has been detected in numerous neoplastic diseases in humans, which indicates the potential role of miRNAs in tumorigenesis. Previous studies have indicated that miRNAs are involved in nearly the entire process of tumor development. MicroRNA-302a, miR-302b, miR-302c, miR-302d, and miR-367 are members of the miR-302/367 cluster that plays various biological roles in diverse neoplastic diseases by targeting different genes. These miRNAs have been implicated in several unique characteristics of cancer, including the evasion of growth suppressors, the sustained activation of proliferative signaling, the evasion of cell death and senescence, and the regulation of angiogenesis, invasion, and metastasis.This review provides a critical overview of miR-302/367 cluster dysregulation and the subsequent effects in cancer and highlights the vast potential of members of this cluster as therapeutic targets and novel biomarkers. K E Y W O R D Sbiological phenomena, cell dedifferentiation, MIRN302, neoplasm, therapy

show abstract

Section: Microrna‐302 Cluster Is An Emerging Potential Biomarker or Tmentioning

confidence: 99%

Application of the microRNA‐302/367 cluster in cancer therapy

Liu

Wang

et al. 2020

Cancer Science

View full text Add to dashboard Cite

show abstract

“…In our studies, we obtained a reprogramming efficiency of 0.8% by applying the same protocol to NuFFs, this was probably caused by lab-to-lab or material variabilities. Furthermore, the use of adult fibroblasts or fibroblasts from diseased patients as well as the use of other somatic cells can result in other reprogramming efficiencies [6, 24, 37]. Therefore, reprogramming protocols should be tested and optimized for each cell type [7].…”

Section: Discussionmentioning

confidence: 99%

Generation of iPSCs by Nonintegrative RNA-Based Reprogramming Techniques: Benefits of Self-Replicating RNA versus Synthetic mRNA

Steinle

Weber

Behring

et al. 2019

Stem Cells International

View full text Add to dashboard Cite

The reprogramming of somatic cells into induced pluripotent stem cells (iPSCs) is gaining in importance in the fields of regenerative medicine, tissue engineering, and disease modeling. Patient-specific iPSCs have as an unlimited cell source a tremendous potential for generating various types of autologous cells. For the future clinical applicability of these iPSC-derived cells, the generation of iPSCs via nongenome integrating methods and the efficient reprogramming of patients’ somatic cells are required. In this study, 2 different RNA-based footprint-free methods for the generation of iPSCs were compared: the use of synthetic modified messenger RNAs (mRNAs) or self-replicating RNAs (srRNAs) encoding the reprogramming factors and GFP. Using both RNA-based methods, integration-free iPSCs without genomic alterations were obtained. The pluripotency characteristics identified by specific marker detection and the in vitro and in vivo trilineage differentiation capacity were comparable. Moreover, the incorporation of a GFP encoding sequence into the srRNA enabled a direct and convenient monitoring of the reprogramming procedure and the successful detection of srRNA translation in the transfected cells. Nevertheless, the use of a single srRNA to induce pluripotency was less time consuming, faster, and more efficient than the daily transfection of cells with synthetic mRNAs. Therefore, we believe that the srRNA-based approach might be more appropriate and efficient for the reprogramming of different types of somatic cells for clinical applications.

show abstract

“…Human primary fibroblasts were reprogramed by introducing synthetic modified mRNAs coding for reprogramming proteins. MicroRNAs like miRNA-367/302s are used to reprogram human primary fibroblasts into iPSCs[ 39 ]. The mRNA transfection is foot print free reprogramming.…”

Section: Human Ipsc Reprogramming Methodsmentioning

confidence: 99%

Applications of 3D Bioprinted-Induced Pluripotent Stem Cells in Healthcare

Soman¹,

Vijayavenkataraman²

2024

IJB

View full text Add to dashboard Cite

Induced pluripotent stem cell (iPSC) technology and advancements in three-dimensional (3D) bioprinting technology enable scientists to reprogram somatic cells to iPSCs and 3D print iPSC-derived organ constructs with native tissue architecture and function. iPSCs and iPSC-derived cells suspended in hydrogels (bioinks) allow to print tissues and organs for downstream medical applications. The bioprinted human tissues and organs are extremely valuable in regenerative medicine as bioprinting of autologous iPSC-derived organs eliminates the risk of immune rejection with organ transplants. Disease modeling and drug screening in bioprinted human tissues will give more precise information on disease mechanisms, drug efficacy, and drug toxicity than experimenting on animal models. Bioprinted iPSC-derived cancer tissues will aid in the study of early cancer development and precision oncology to discover patient-specific drugs. In this review, we present a brief summary of the combined use of two powerful technologies, iPSC technology, and 3D bioprinting in health-care applications.

show abstract

RNA-based Reprogramming of Human Primary Fibroblasts into Induced Pluripotent Stem Cells

Cited by 12 publications

References 11 publications

Application of the microRNA‐302/367 cluster in cancer therapy

Application of the microRNA‐302/367 cluster in cancer therapy

Generation of iPSCs by Nonintegrative RNA-Based Reprogramming Techniques: Benefits of Self-Replicating RNA versus Synthetic mRNA

Applications of 3D Bioprinted-Induced Pluripotent Stem Cells in Healthcare

Contact Info

Product

Resources

About